GGrantIndex
← Leaderboards

Yun Michael Shim

University Of Virginia

$6,424,060
Attributed
$13,368,383
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.8M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,368,383 · 9

By mechanism

R01$12,616,450 · 6
K08$643,485 · 1
R41$99,674 · 1
M01$8,774 · 1

Top collaborators

Most similar at University Of Virginia

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungTissuesPulmonary EmphysemaPathogenesisInflammationBiologyIn VivoSeveritiesAnatomyResponseDiagnosticPhenotypeResolutionCigarette SmokeLung DiseasesDiagnosisPhysiologicalLeadPathway InteractionsPatternChronicMortalityAirway ObstructionDisease Progression

Grant awards (25)

Dissolved Phase Hyperpolarized Xenon-129 MRI: a novel biomarker to quantify pulmonary pathology in young healthy e-cigarette users$739,319
R01 · FY2025 · DA · contact PI
Developing Hyperpolarized Gas MRI signatures to detect and manage acute cellular rejection$728,628
R01 · FY2025 · HL
Sexual dimorphism in susceptibility to emphysematous tissue injury$728,054
R01 · FY2025 · HL · contact PI
Multi-omic Characterization of COPD in Females$552,040
R01 · FY2025 · HL
Dissolved Phase Hyperpolarized Xenon-129 MRI: a novel biomarker to quantify pulmonary pathology in young healthy e-cigarette users$754,391
R01 · FY2024 · DA · contact PI
Developing Hyperpolarized Gas MRI signatures to detect and manage acute cellular rejection$742,810
R01 · FY2024 · HL
Sexual dimorphism in susceptibility to emphysematous tissue injury$715,914
R01 · FY2024 · HL · contact PI
Multi-omic Characterization of COPD in Females$572,076
R01 · FY2024 · HL
Sexual dimorphism in susceptibility to emphysematous tissue injury$773,943
R01 · FY2023 · HL · contact PI
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$786,595
R01 · FY2021 · HL · contact PI
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$786,595
R01 · FY2020 · HL · contact PI
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$786,595
R01 · FY2019 · HL · contact PI
Discovery of New Anti-Inflammatory Agents to Treat COPD$583,478
R01 · FY2019 · HL
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$780,775
R01 · FY2018 · HL · contact PI
Discovery of New Anti-Inflammatory Agents to Treat COPD$583,648
R01 · FY2018 · HL
Hyperpolarized Xenon-129 MRI: a new multi-dimensional biomarker to determine pulmonary physiologic responses to COPD therapeutics$775,267
R01 · FY2017 · HL · contact PI
Discovery of New Anti-Inflammatory Agents to Treat COPD$606,053
R01 · FY2017 · HL
Discovery of New Anti-Inflammatory Agents to Treat COPD$620,269
R01 · FY2016 · HL
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema$99,674
R41 · FY2013 · HL
Biology of Leukotrienes in the Pathogenesis of Emphysema$128,697
K08 · FY2012 · HL · contact PI
Biology of Leukotrienes in the Pathogenesis of Emphysema$128,697
K08 · FY2011 · HL · contact PI
Biology of Leukotrienes in the Pathogenesis of Emphysema$128,697
K08 · FY2010 · HL · contact PI
Biology of Leukotrienes in the Pathogenesis of Emphysema$128,697
K08 · FY2009 · HL · contact PI
BIOLOGY OF CYTOKINES AND 5-LO IN THE PATHOGENESIS OF EMPHYSEMA$8,774
M01 · FY2009 · RR · contact PI
Biology of Leukotrienes in the Pathogenesis of Emphysema$128,697
K08 · FY2008 · HL · contact PI